Arbutus Biopharma Corporation (NASDAQ:ABUS) last traded at $6.53 with shares having a low of $5.80 and high of $6.90. This range of trading makes the stock one of the most volatile of the day.
Not surprisingly, $6.90 is the stock’s 52 week high. It is among the market’s biggest gainers today. Company shares are trading at $6.53 quite a bit higher than $4.08, the 50 day moving average and which is significantly higher than the 200 day moving average of $3.58. The 50 day moving average went up $2.45 or +60.036% and the 200 day average was up $2.95.
Traders are feeling more bullish on Arbutus Biopharma Corporation as shown by the fall in short interest. The firm realized a fall in short interest of -24.05% as of the latest report on August 31, 2017. Short shares decreased from 550,388 to 418,041 over that timeframe. Days to cover decreased -3.0 to 5.0 and the percentage of shorted shares is 0.01% as of August 31.
Here is a rundown on some insider market activity for Arbutus Biopharma Corporation (NASDAQ:ABUS). Michael J. Sofia, Chief Scientific Officer disclosed the sale of 30,000 shares of ABUS stock. The shares were purchased at an average price of $3.71. Sofia now owns $635,939 of the stock per the Form 4 SEC filing. In the latest earnings report the EPS was $-5.07 and is estimated to be $-1.46 for the current year with 55,026,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.42 with next year’s EPS projected to be $-1.42.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada..